The two-compartment pharmacokinetic model described the mechanisms how human body handles with ingestion of NC-cyclodextrin complexes in gastrointestinal tract (GI), distribution in the blood (Plasma) ...

The pharmacokinetics of erlotinib was described by a two-compartment model with first order extravascular absorption kinetics. There was a time delay of approximately 2 h between erlotinib plasma ...

A linear two-compartment model was shown to be adequate to describe data. ... British Journal of Cancer - Population pharmacokinetics of the humanised monoclonal antibody, HuHMFG1 ...

Pharmacokinetics. The parameter and OBJs values for the base 1-, 2-, and 3-compartment models are summarized in Table 1.As found in the separate modeling of the intravenous and nasal data, the 2 ...

A population pharmacokinetic model was designed and validated to describe the pharmacokinetics of E7070 at all four treatment schedules and to identify the ... The data were best described using a ...

PURPOSE: N-(3-Chloro-7-indolyl)-1,4-benzenedisulfonamide (E7070) is a novel sulfonamide anticancer agent currently in phase II clinical development for the treatment of solid tumors. Four phase I ...

Pharmacokinetic Data Analysis. Intravenous Data. Standard 1-, 2-, and 3-compartment models were fitted to the concentration-time data for the intravenous doses.